Literature DB >> 22874898

Assessment of effective absorbed dose of (111)In-DTPA-Buserelin in human on the basis of biodistribution rat data.

Afsaneh Lahooti1, Saeed Shanehsazzadeh, Amir Reza Jalilian, Mohammad Bagher Tavakoli.   

Abstract

In this study, the effective absorbed dose to human organs was estimated, following intra vascular administration of (111)In-DTPA-Buserelin using biodistribution data from rats. Rats were sacrificed at exact time intervals of 0.25, 0.5, 1, 2, 4 and 24 h post injections. The Medical Internal Radiation Dose formulation was applied to extrapolate from rats to humans and to project the absorbed radiation dose for various human organs. From rat data, it was estimated that a 185-MBq injection of (111)In-DTPA-Buserelin into the human might result in an estimated absorbed dose of 24.27 mGy to the total body and the highest effective absorbed dose was in kidneys, 28.39 mSv. The promising results of this study emphasises the importance of absorbed doses in humans estimated from data on rats.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22874898     DOI: 10.1093/rpd/ncs137

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  3 in total

1.  Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.

Authors:  Ashraf Fakhari; Amir R Jalilian; Hassan Yousefnia; Saeed Shanehsazzadeh; Ali Bahrami Samani; Fariba Johari Daha; Mehdi Shafiee Ardestani; Ali Khalaj
Journal:  Mol Imaging Radionucl Ther       Date:  2015-10-05

2.  Development of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI.

Authors:  Amir Gholami; Seyyed Hossein Mousavie Anijdan
Journal:  Iran J Basic Med Sci       Date:  2016-10       Impact factor: 2.699

3.  Preclinical Evaluation of 68Ga-MAA from Commercial Available 99mTc-MAA Kit.

Authors:  Saeed Shanehsazzadeh; Amir Reza Jalilian; Afsaneh Lahooti; Parham Geramifar; Davood Beiki; Hassan Yousefnia; Amir Rabiee; Mohammad Mazidi; Seyedeh Fatemeh Mirshojaei; Stephan Maus
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.